Answers are grounded in this paper and cite their sources.
Live viral vaccines have long been recognized as among the most effective interventions to prevent viral diseases. In principal, such vaccines represent modified versions of the original pathogen with reduced virulence but retained ability to stimulate an immune response that is identical or very similar to that induced by natural infection. Various approaches have been used to generate attenuated vaccine viruses, including use of related non-human viruses (smallpox, rotavirus), administration at difference body sites (adenovirus), and laboratory adaptation (polio and others). For many viruses, such vaccines are able to induce lifelong immunity, just like that induced by virulent infection with the original virus. For those viruses that occur only in humans, highly effective live viral vaccines have eradicated (smallpox) or have the potential to eradicate (polio, measles) the pathogen from existence. The potential development of live vaccines for influenza was first suggested in 1937, shortly after influenza virus was first demonstrated to be the cause of influenza. Smorodintseff and colleagues noted that influenza virus, after serial passage in mice and ferrets, rarely induced febrile illness in humans after a quasi-aerosol administration. Many patients could not be infected because they had preexisting neutralizing antibody. In addition, most patients who did become infected developed substantial increases in such antibody in their serum, even if they did not experience symptoms. The authors concluded that “these data permit one to conclude that inhalation of influenza virus, attenuated by protracted passage through ferrets and mice, may be worthy of attention as a means of increasing the quantity of protective antibodies in human beings, and perhaps also, of enhancing their resistance to a subsequent influenza infection” [1]. The editor of the journal, in a footnote, did not agree, stating that “such a suggestion is dangerously premature, unless regarded as a working hypothesis to be tested by limited trial on strictly experimental lines.” Although much has been accomplished since then, there remains much more to be done. Development of live vaccines for influenza is faced with the problem that it is likely that the vaccine would need to be reformulated frequently in order to keep pace with antigenic evolution, similar to the strategy for inactivated vaccine. To solve this problem, the usual approach has been to take advantage of the segmented nature of the genomes of influenza A and B viruses and incorporate attenuating mechanisms into the so-called internal gene segments, that is, gene segments other than HA and NA, in order to create a master donor virus (MDV). The MDV is then paired with the HA and NA genes specific for the seasonal (or pandemic) virus to generate an antigenically matched vaccine (Figure 1). A requirement for this approach is that the attenuation and immunogenicity of the resulting vaccine virus does not vary with different HA and NA gene combinations. The basic strategy of creating updated live attenuated influenza vaccines, taking care of the segmented nature of the influenza virus genome. Attenuating mutations are placed at various locations within the 6 “internal” gene segments of the genome of a master donor virus (MDV), that is, the PA, PB1, PB2, NP, M, and NS gene segments. New antigenic vaccine variants are then created by combining the HA and NA genes of the desired vaccine candidate with the internal genes of the MDV. The specific mutations in the MDV are different for each attenuated vaccine platform. The basic strategy of creating updated live attenuated influenza vaccines, taking care of the segmented nature of the influenza virus genome. Attenuating mutations are placed at various locations within the 6 “internal” gene segments of the genome of a master donor virus (MDV), that is, the PA, PB1, PB2, NP, M, and NS gene segments. New antigenic vaccine variants are then created by combining the HA and NA genes of the desired vaccine candidate with the internal genes of the MDV. The specific mutations in the MDV are different for each attenuated vaccine platform. Early attempts to develop live influenza vaccines utilized a variety of methods to induce attenuation in the candidate virus. Based on the concept that the temperature of the upper respiratory tract is lower than the temperature of the lower respiratory tract, viruses that manifested restricted replication at high temperature, that is, temperature-sensitive (ts) viruses, were a logical approach to vaccine development. Such viruses could be generated by chemical mutagenesis of wild-type viruses. A number of such ts viruses were evaluated as potential vaccines [2]. In general, these candidates did demonstrate both attenuation and immunogenicity in animal models and in limited trials in healthy adults [3, 4]. However, the ts phenotype in these viruses was typically due to a small number of mutations. As a result, phenotypic reversion occurred frequently, both as a result of reversion mutations as well as extragenic suppressor mutations [5, 6]. Largely for this reason, the use of chemically derived ts viruses was not pursued further. Another novel approach to developing a live, attenuated influenza vaccine (LAIV) was based on the observation that avian influenza viruses, in general, are quite restricted in their ability to replicate in humans. Early studies demonstrated that a variety of avian viruses replicated to only low levels when administered intranasally to humans [7]. Similar results were seen when the highly egg-adapted laboratory A/PR8 virus was administered to humans. Because this approach involves use of an animal virus as the basis for a human vaccine, somewhat similar to the smallpox vaccine, it is sometimes referred to as a “modified Jennerian approach” [8]. Avian viruses were thought to be naturally attenuated in humans because of their extensive adaptation to avian cells. Although the specific mechanisms of this adaptation were not completely known, it was felt that such adaptation would not be likely to undergo loss of attenuation, or phenotypic reversion, upon growth in humans, which is in contrast to the experience with ts variants. This was in fact the case in clinical trials. A variety of potential avian viruses were evaluated as vaccine candidates. The avian A/Mallard/NY/1978 (H4NX) exhibited the best performance in early clinical trials [9]. Evaluation of single gene reassortants in studies in non-human primates (NHP) and in humans suggested that combinations of the M, NP, and PB2 genes contributed to conferring attenuation to human seasonal viruses, although the specific contributions differed between human and NHP studies [10, 11]. However, the specific differences in these genes that resulted in relative attenuation in humans were not determined. A number of studies were performed to compare the attributes of potential LAIV generated by reassortment with the A/Mallard/78 virus and those generated by reassortment with the cold-adapted A/Ann Arbor/6/60 virus (see below). These studies suggested that the avian human virus was somewhat more immunogenic than the cold-adapted virus in serosusceptible adults [12]. However, in head-to-head comparisons in children, the avian–human virus was associated with mild febrile responses in some children, without significant immunologic advantages [13, 14]. For this reason and because there was no feasible strategy to use avian viruses to develop influenza B vaccines at the time, further development of avian–human reassortant LAIV was discontinued. Currently licensed LAIV are based on a slightly different strategy for generating MDV, the development of viruses that were both cold-adapted (ca), meaning that they could replicate at lower temperatures compared with wild-type (wt) viruses, and were also ts, generally defined as a 2-log10 or greater reduction in replication at an elevated temperature. Such viruses were derived in a classic fashion by serial passage of a wt virus in eggs at gradually decreasing temperatures. This approach was used to generate several live, attenuated influenza A and influenza B viruses that subsequently became the basis for licensed LAIV in use today. In the United States, these are live viruses based on the ca A/Ann Arbor/6/60 and B/Ann Arbor/1/66 viruses developed in the laboratory of Dr John Maasab [15]. Multiple clinical studies of reassortant vaccine viruses that bear internal gene segments from the ca Ann Arbor A and B MDV and HA and NA genes from a variety of wt viruses were well tolerated in serosusceptible healthy adults compared with the corresponding wt virus, with lower levels of viral replication and no significant influenza-like illness. In contrast to the earlier experiences with ts vaccine viruses, the ca MDV have multiple genes that contribute to the attenuation phenotype. This was most clearly demonstrated in a series of clinical studies with single-gene reassortant viruses in which the contribution of each individual gene to the attenuation of the A/Ann Arbor/6/60 virus was evaluated. It was demonstrated that the PB1, PB2, PA, and possibly the M gene segment each independently contribute to attenuation [16, 17]. Other studies that used reverse genetic approaches identified multiple specific mutations as contributing to the ts phenotype of this virus [18]. For the influenza B/Ann Arbor virus, the PA, PB2, NP, and M gene segments were shown to contribute to the cold-adapted and attenuation phenotypes [19, 20]. The genetic basis of attenuation of the A/Leningrad/66 MDV and B/USSR/70 viruses have not been studied in as much detail, but all of these viruses have multiple mutations compared with the wild-type starting material. Consequently, phenotypic reversion has not been observed with the ca MDV either in vitro or in vivo. These studies have included multiple serial passage at elevated temperature in cell culture, as well as several studies of animal-to-animal passage. In addition, clinical studies have demonstrated phenotypic stability even after prolonged replication in seronegative children [21]. Early studies showed that shedding of the ca Ann Arbor LAIV by adults is of low titer and short duration [22] and that transmission of LAIV to contacts was rare. In the largest study, 197 children aged between 8 and 36 months in a daycare setting were randomized to receive LAIV or placebo. LAIV was detected in only 1 placebo recipient [23]. Based on these studies, transmission of vaccine virus to contacts is expected to be rare. Current recommendations restrict use only in patients who are close contacts with extremely immunosuppressed persons (eg, those who require a protected environment) [24]. Initial evaluation of the cold-adapted LAIV took place in adults, largely sponsored by the US National Institutes of Health. These studies showed that adults generally had low rates of serum antibody response after LAIV [25, 26]. Even in those prescreened to have low prevaccination vaccine-specific influenza antibody, the rates of serum antibody responses to intranasal LAIV in adults were low [26]. Mucosal immune responses assessed by HA-specific immunoglobulin A enzyme-linked immunosorbent assay in nasal secretions were higher, suggesting that nasal mucosal immunity might play a major role in the protective efficacy of the vaccine [27]. Most susceptible children demonstrate measurable serum and mucosal HA-specific antibody responses, and mucosal responses have been demonstrated in up to 85% of young children after LAIV [28]. Limited studies suggested that detectable immune responses in the elderly are relatively rare [29, 30]. The attenuation and protective efficacy of the cold-adapted LAIV has been tested extensively in the controlled human infection model, taking advantage of the simultaneous production and availability of both the reassortant vaccine virus and the parent wild-type virus. These studies were used to determine the genetic basis of attenuation of the vaccine [16] as well as to discover immunologic correlates of protection in the model [31]. These studies demonstrated protective efficacy of both monovalent cold-adapted H1N1 [32] and H3N2 [33, 34] against homologous influenza A challenge and the protection of monovalent cold-adapted influenza B against influenza B challenge [35]. A large prelicensure challenge study was then conducted using a trivalent preparation of the vaccine, with individuals selected based on low levels of serum antibody who were administered the H1N1, H3N2, or B wild-type component of the vaccine. Overall, infection rates of each wild-type virus in placebo recipients were lower than expected. However, when the results of all 3 challenges were pooled, the trivalent LAIV showed significant protection against laboratory-documented infection [26]. Over many years of development prior to attempts to license the vaccine, a number of small-scale field trials of efficacy were performed using monovalent or bivalent formulations of the vaccine. In the largest randomized, controlled study in healthy persons aged 1 through 64 years, most of whom were adults, the efficacy of a prelicensure, bivalent preparation of LAIV for preventing culture-confirmed influenza A illness in adults was 85% (95% confidence interval [CI], 70% to 92%) for H1N1 and 58% (95% CI, 29% to 75%) for H3N2 [36]. As part of the critical phase 3 demonstration of efficacy, LAIV was evaluated in a large study against nonlaboratory-confirmed clinical endpoints performed in 4561 healthy working adults [37]. In this study, the effectiveness of LAIV in preventing severe febrile respiratory illness of any cause during the influenza season was 29%. LAIV was demonstrated to be efficacious in the prevention of influenza in a 2-year, randomized, placebo-controlled trial conducted in 1314 children aged 15 to 74 months. Efficacy against culture-confirmed influenza illness in the first year of this trial was 95% against influenza A/H3N2 and 91% against influenza B [38]. In the second year of the trial, the H3 component of the vaccine (A/Wuhan/93) was not a close match with the predominant H3 virus that season, A/Sydney/95. However, the efficacy of ca LAIV against this variant was 86% (95% CI, 75% to 92%) [39], suggesting that cold-adapted influenza vaccine (CAIV) can induce protective immunity against drift variants. Overall, the efficacy of LAIV to prevent any influenza illness during the 2-year period of surveillance in this field study was 92% (95% CI, 88% to 94%). The high levels of efficacy in immunologically susceptible children was very encouraging, given that this age group is at higher risk of severe disease and influenza-related complications [40]. Cold-adapted LAIV based on the Ann Arbor MDV have been well tolerated in both adults and children in studies conducted over many years. However, in the largest trial to evaluate safety in children, medically significant wheezing within 42 days of vaccination was reported in 3.8% of children aged <2 years after receipt of LAIV compared with 2.1% in those who received inactivated influenza vaccine (IIV) [41]. The mechanisms by which LAIV might be associated with wheezing remain unclear, and many wheezing episodes occurred well outside of the window during which vaccine virus replication would be expected. However, because of this observation, LAIV is currently approved for use in the United States for children aged ≥2 years who do not have a history of asthma. Subsequent post-licensure studies have confirmed the efficacy of LAIV in children [42, 43]. Studies in older adults have shown LAIV to be well tolerated but to generate lower frequencies of measurable immune responses [44, 45], leading to doubts about the potential efficacy of the vaccine in the elderly. In one randomized, double-blind, placebo-controlled clinical trial of LAIV among community-dwelling ambulatory adults aged ≥65 years, the overall efficacy of LAIV against viruses that were antigenically similar to the vaccine was 42% [46]. In retrospect, this may not really be substantially different than the expected efficacy of inactivated vaccine in that population. However, LAIV is currently only indicated for use in adults aged ≤49 years. Because LAIV and IIV stimulate different types of immune response (mucosal or systemic antibody), there has been interest in whether combined approaches would be useful. In one small randomized study conducted over 3 seasons in skilled nursing facilities, the combination of monovalent LAIV and trivalent IIV and percent greater efficacy in prevention of respiratory illness due to the influenza subtype contained in the LAIV compared to IIV alone [47]. However, a subsequent study done in younger ambulatory patients with chronic obstructive pulmonary disease (COPD) demonstrated no benefit of combined LAIV plus IIV in prevention of exacerbations of COPD [48]. While relatively few randomized direct comparisons of the efficacy of live and inactivated vaccines have been performed, the available studies are consistent with the observed effects of age and prior influenza experience on immunogenicity. When these vaccines were compared in young children aged 12 months through 59 months, LAIV showed consistently superior protection, with an approximately 50% greater protective efficacy than inactivated vaccine [41, 49]. In contrast, studies that directly compared the vaccines in adults have suggested that the vaccines have similar efficacy or that IIV vaccine is slightly more efficacious than live vaccine. In one 3-armed study, the efficacy of LAIV compared with placebo for prevention of laboratory-confirmed influenza in healthy adults was 57%, while the efficacy of IIV was 77%. However, the difference between the 2 vaccines was not statistically significant [50]. In a subsequent season in the same population, the absolute efficacies of IIV and LAIV were 68% and 36%, respectively [51]. In an effectiveness assessment in the US military, the effectiveness of IIV against medical visits for or other influenza-related was higher than that of for who had not been in years When the H1N1 component of LAIV was by a virus with the HA and NA of an virus the there was a substantial in effectiveness of against H1N1 This effectiveness was demonstrated in the United States to a in other The for the effectiveness of this are not completely but may be related to the replication of the specific H1N1 virus, increasing levels of immunity in the population, or other However, as a result, use of LAIV in the United States was not by on for several years. the H1N1 component has been updated with a virus that to generate immune responses, and use of LAIV has passage at lower temperature was also used to develop the ca and MDV. based on this strategy have been licensed in several in In general, clinical trials with these MDV showed results that were similar to those with the Ann Arbor MDV and are not in studies of vaccine in children in showed 58% efficacy in prevention of while a similar study conducted in showed no of The for these differences are unclear, although viruses a role in the study in and subsequent studies have demonstrated relatively shedding and immunogenicity of the component of the vaccine some of the same that to reduced effectiveness of the Ann vaccine might also have the vaccine The development of methods to directly the genome of influenza viruses has multiple for of potential including of genes and in the of the vaccine. In addition, of influenza using administered such as has also been as a strategy to similar immune of these approaches have the of field but many are well and be The 1 gene of influenza A and B virus a gene that is not into but multiple in the viral including of the or of the NS gene has been as a strategy for attenuating influenza viruses. of influenza A and B viruses with genes were shown to be highly attenuated in animal models and to protection against wild-type challenge Subsequent phase 1 studies in humans have demonstrated monovalent and to be well tolerated in healthy adults and to stimulate serum and mucosal Because the virus is replication vaccine virus is not from nasal secretions after A second of vaccine is one in which the gene of influenza A virus is Because is for and viral this strategy also a Evaluation of vaccine viruses in mice and ferrets has shown to be highly immunogenic and to immune responses and protection against both seasonal and viruses because the immunogenicity of the vaccine does not on of the virus, the vaccine generated immune response in with preexisting immunity Another approach to development of live, attenuated vaccines is referred to as The approach advantage of the observation that of are used substantially more frequently than other viruses that use the of substantial and attenuation can be Because the of the is not this approach could generate more immune responses than LAIV approaches studies of LAIV candidates with NA and HA genes demonstrated that these viruses replicate in cell but with of HA and In the model, the virus exhibited reduced clinical disease but similar replication compared with the wild-type virus and protection against subsequent homologous wild-type challenge In a model, the LAIV exhibited reduced replication and clinical attenuation and substantial protection against subsequent homologous wild-type challenge In both the vaccine was highly immunogenic the reduced of HA and A phase 1 clinical trial of the vaccine is attenuated vaccines remain a highly approach to influenza for multiple infection a and immune as by the of high of antibody to viruses in individuals who were infected years earlier As use of live, attenuated vaccines is the only approach that has eradicated or eradicated human diseases. are of all of the immune including mucosal and systemic and In addition, vaccination approaches are highly from an of in the development of live vaccines for influenza be the ability to use at very early in order to the first to influenza and and the response to subsequent This may be an extremely component in the development of live vaccines as potential approaches to or protective influenza vaccines this require a between the replication of the vaccine virus and the clinical and immunogenicity of the vaccine. This as part of the and sponsored by of reported authors have the for of that the to the of the have been
No takes yet. Share an insight, caveat, or question.
John J. Treanor (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: